Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023

Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.

[thumbnail of Fact Sheet Nr.140_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
129kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 800-910 Breast
Language:	English
Series Name:	Fact Sheet Nr. 140
Deposited on:	21 Aug 2023 14:15
Last Modified:	28 Dec 2023 13:24

Repository Staff Only: item control page